Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PRCS vs MEDX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MEDX Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

MEDX Overall Winner 6-Pillar Tally: PRCS 0 – 0 MEDX (6 Tie) Matrix Metrics: PRCS 1 – 2 MEDX

As of Nov 16, 2026, Horizon Kinetics Medical ETF (MEDX) is the stronger overall head-to-head candidate over Parnassus Core Select ETF (PRCS) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). PRCS carries a Unified Composite Score of 50.7/100 (HOLD) at $28.53 (N/M Forward P/E, N/A operating margin), whereas MEDX carries 42.6/100 (HOLD) at $37.66 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While PRCS currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. MEDX 42.6/100 HOLD), MEDX captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Technical & Structure Timing Caution: PRCS is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.3); meanwhile MEDX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PRCS vs MEDX
PRCS NYSE
Parnassus Core Select ETF
Institutional Equity
$28.53
-1.62% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 22% Vol
Unified Composite Score
50.7 / 100 HOLD
Tech 49.0 Fund 51.0 Flow 50.0 Mom 55.3
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.5%) with fading momentum, RSI 43
RSI-14: 43.3 · SMA20: $28.99 · SMA50: $28.88
MEDX NASDAQ Head-to-Head Winner
Horizon Kinetics Medical ETF
Institutional Equity
$37.66
-0.92% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.34β · 19% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 42.0 Fund 45.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.0% over 20 days), RSI 55
RSI-14: 54.9 · SMA20: $37.57 · SMA50: $36.19

6-Pillar Scorecard Institutional Category Breakdown (PRCS 0 – 0 MEDX)

Columns: Metric · PRCS · MEDX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PRCS (1) vs MEDX (2)
Institutional Metric PRCS MEDX Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
75% ($24–$30) 87% ($32–$39) Stronger Trend MEDX
Beta / 30D Volatility
Risk Regime
0.92β · 22% Vol 0.34β · 19% Vol Lower Realized Risk MEDX
Unified Institutional Score
Composite Signal
50.7 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite PRCS
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MEDX +6.29 pp
PRCS: -1.68% · MEDX: +4.61%
3M Horizon MEDX +5.24 pp
PRCS: -2.03% · MEDX: +3.21%
6M Horizon MEDX +12.06 pp
PRCS: +3.72% · MEDX: +15.78%
1Y Horizon MEDX +7.26 pp
PRCS: +8.07% · MEDX: +15.33%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PRCS vs MEDX. Trailing 12-month operating profitability (PRCS N/A vs MEDX N/A) and valuation multiples (PRCS N/M vs MEDX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PRCS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
MEDX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PRCS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PRCS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MEDX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MEDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PRCS Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MEDX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PRCS vs MEDX Key Questions & Quantitative Answers

As of Nov 16, 2026, Horizon Kinetics Medical ETF (MEDX) is the stronger overall head-to-head candidate over Parnassus Core Select ETF (PRCS) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). PRCS carries a Unified Composite Score of 50.7/100 (HOLD) at $28.53 (N/M Forward P/E, N/A operating margin), whereas MEDX carries 42.6/100 (HOLD) at $37.66 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While PRCS currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. MEDX 42.6/100 HOLD), MEDX captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: PRCS is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.3); meanwhile MEDX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PRCS and MEDX split Growth & Scale metrics: PRCS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with MEDX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, PRCS generates N/A in USD-normalized revenue versus N/A for MEDX. In operating R&D and SG&A reinvestment, PRCS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MEDX.

PRCS and MEDX trade at balanced relative valuation multiples. PRCS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MEDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PRCS (N/A ROE) versus MEDX (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, PRCS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 22% Vol realized risk). By comparison, MEDX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.34β · 19% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.